The effects of antitussive treatment of ACE inhibitor-induced cough on therapy compliance: A prescription sequence symmetry analysis

Drug Safety

Volumn 36, Issue 6, 2013, Pages 435-439

  Vegter, Stefan ^a   De Boer, Pieter ^a   Van Dijk, Klaas Willem ^a   Visser, Sipke ^a   De Jong Van Den Berg, Lolkje T W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITUSSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; COMMUNITY; COUGHING; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ANTITUSSIVE AGENTS; COUGH; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYPERTENSION; INAPPROPRIATE PRESCRIBING; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; PHARMACIES;

EID: 84878688607     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0024-z     Document Type: Article

References (28)

1. Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J. 2009;30(11):1385-94.
2. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941-51.
3. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359-64.
4. Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 1996;15(1):72-8.
5. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234-42.
6. Gibson GR. Enalapril-induced cough. Arch Intern Med. 1989;149(12):2701-3.
7. Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Female preponderance for lisinopril-induced cough in hypertension. Am J Hypertens. 1994;7(11):1012-5.
8. Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499-509.
9. Morice AH, Kastelik JA. Cough. 1: chronic cough in adults. Thorax. 2003;58(10):901-7.
10. Pavord ID, Chung KF. Management of chronic cough. Lancet. 2008;371(9621):1375-84.
11. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):169S-73S.
12. Lombardi C, Crivellaro M, Dama A, Senna G, Gargioni S, Passalacqua G. Are physicians aware of the side effects of angiotensin-converting enzyme inhibitors?: a questionnaire survey in different medical categories. Chest. 2005;128(2):976-9.
13. Vegter S. de Jong-van den Berg LT. Misdiagnosis and mistreatment of a common side-effect-angiotensin-converting enzyme inhibitor-induced cough. Br J Clin Pharmacol. 2010;69(2):200-3.
14. Olsen CG. Delay of diagnosis and empiric treatment of angiotensin-converting enzyme inhibitor-induced cough in office practice. Arch Fam Med. 1995;4(6):525-8.
15. Kalisch LM, Caughey GE, Roughead EE. The prescribing cascade. Aust Prescr. 2011;34(6):162-6.
16. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096-9.
17. Wallenius SH, Vainio KK, Korhonen MJ, Hartzema AG, Enlund HK. Self-initiated modification of hypertension treatment in response to perceived problems. Ann Pharmacother. 1995;29(12):1213-17.
18. Schirm E, Monster TB, de Vries R, van den Berg PB, de Jong-van den Berg LT, Tobi H. How to estimate the population that is covered by community pharmacies? An evaluation of two methods using drug utilisation information. Pharmacoepidemiol Drug Saf. 2004;13(3):173-9.
19. Tobi H, van den Berg PB, de Jong-van den Berg LT. The interaction database: synergy of science and practice in pharmacy. In: Brause RW, Hanisch E, editors. Medical data analysis. Berlin: Springer; 2000. p. 206-11.
20. Leufkens HGM, Urquhart J. Automated pharmacy record linkage in the Netherlands. In: Strom BL, editor. Pharmacoepidemiology. Chichester: Wiley; 2008. p. 347-60.
21. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7(5):478-84.
22. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7.
23. Vegter S, Nguyen NH, Visser ST, de Jong-van den Berg LT, Postma MJ, Boersma C. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care. 2011;17(9):609-16.
24. Amin AP, Mukhopadhyay E, Nathan S, Napan S, Kelly RF. Association of medical noncompliance and long-term adverse outcomes, after myocardial infarction in a minority and uninsured population. Transl Res. 2009;154(2):78-89.
25. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772-9.
26. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12(5):639-45.
27. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303-10.
28. Böhm M, Baumhäkel M, Mahfoud F, Werner C. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors. Cardiology. 2010;117(3):163-73.